Trends in the use of hospital beds by older people in Australia: 1993-2002 by Mackay, M. & Millard, P.
 PUBLISHED VERSION  
 
Mackay, Mark Andrew Maio; Millard, Peter H.  
Trends in the use of hospital beds by older people in Australia: 1993-2002 Medical Journal of 
Australia, 2005; 182(5):252-252 
 




























This document has been archived with permission from the editor of the Medical 




MJA • Volume 182 Number 5 • 7 March 2005
LETTERS 
Severe childhood pneumonitis caused by the Queensland strain of 
community-acquired methicillin-resistant Staphylococcus aureus
249 Bradley T Martin, Pamela Palasanthiran, Iain B Gosbell,
Thelma Barbagiannakos, Emma J Best, Richard L Henry
Impact of a formal removal policy for central venous catheters 
on duration of catheterisation
249 John R Gowardman, Catherine Kelaher, Joy Whiting, Peter J Collignon
Inhalation-device polypharmacy in asthma
250 Vanessa M McDonald, Peter G Gibson
Smoking and pregnancy
251 Raoul A Walsh, Judith Lumley
252 Jessica H Ford, Annette J Dobson
Trends in the use of hospital beds by older people in Australia: 1993–2002
252 Mark Mackay, Peter Millard
253 Len C Gray, Stephen J Duckett
Whistleblowing in the Australian public hospital system
253 Paddy A Dewan
The direct thrombin inhibitor melagatran/ximelagatran
254 Luke R Bereznicki, Shane L Jackson, Gregory M Peterson
Australasian Association of Doctors’ Health Advisory Services




234 Gripped with pain
John C Tuffley
202 IN THIS ISSUE
248 IN OTHER JOURNALS
Cover image courtesy: Professor Richard D M Allen, Director of Transplantation 
Services, Royal Prince Alfred Hospital.
From the Editor’s Desk
A MEETING TOO MANY
“Sorry, [he or she] is in a meeting” 
commonly frustrates attempts to talk to 
people in academia, hospitals or 
bureaucracy. It appears these organisations 
are afflicted with the modern epidemic of 
ever-increasing growth of committees, 
conferences, retreats and workshops and 
institutional meetings. 
The purpose of a meeting is simple: to 
deliberate, debate and decide. Anything else 
is superfluous. But, inevitably, this purpose 
is hijacked. Some see meetings as an 
opportunity to communicate, obfuscate or 
obstruct. Others use meetings to create the 
illusion of participatory decision-making, 
when decisions have already been made 
elsewhere. Power seekers dominate, and 
ineffective chairpersons tend to tolerate 
their behaviour — all the while the meeting 
time ticks on.
What to do?
Abraham Bergman, a US physician, 
recommends all-out war — a 31-day 
moratorium on all meetings involving more 
than three people, conference rooms to be 
locked and the chairs thrown out! After this 
period of enforced “cold turkey”, there 
should be a careful and structured return of 
meetings, provided their stated purpose is 
decision-making. 
Further suggestions range from a 
reduction in meeting time from the 
maximum 50 to 15 minutes, to meetings 
held without chairs, or even convened in 
corridors. Chairpersons should ensure full 
participation, quashing repetitive rambling, 
and should close the meeting on time. 
Ineffective chairpersons should seek 
remedial therapy for their failings. Finally, 
participants in meetings should continually 
ask themselves whether this is optimal use 
of their time.
Perhaps we would be better served by 
reflecting on a comment by renowned US 
columnist Dave Barry — “If you had to 
identify, in one word, the reason why the 
human race has not achieved, and never will 
achieve, its full potential, that word would 
be ‘meetings’.”
Martin B Van Der Weyden
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Letters
Severe childhood pneumonitis 
caused by the Queensland 
strain of community-acquired 
methicillin-resistant 
Staphylococcus aureus
Bradley T Martin,* 
Pamela Palasanthiran,† Iain B Gosbell,‡ 
Thelma Barbagiannakos,§ 
Emma J Best,¶ Richard L Henry**
* Respiratory Fellow (currently, Department of 
Respiratory Medicine, Children’s Hospital at 
Westmead, Locked Bag 4001, Westmead, NSW 2145), 
† Infectious Diseases Specialist, ¶ Infectious Diseases 
Fellow, Sydney Children’s Hospital, Sydney, NSW; 
‡ Director, § Hospital Scientist, SWAPS Staphylococcal 
Reference Facility, South Western Area Pathology 
Service, Sydney, NSW; ** Head of School of Women’s 
and Children’s Health and Senior Associate Dean, 
Faculty of Medicine, University of New South Wales, 
Sydney, NSW. bradleym@chw.edu.au
TO THE EDITOR: We report a case of
severe pneumonia in a previously healthy 3-
year-old girl of European background. Non-
multiresistant methicillin-resistant Staphylo-
coccus aureus (MRSA) was isolated from her
sputum, and she was treated with intra-
venous vancomycin, followed by oral
rifampicin and fusidic acid.
After antibiotic therapy ceased, symptoms
recrudesced, and computed tomography of
the chest showed bronchiectasis. Sputum
again grew MRSA (now also resistant to
rifampicin, fusidic acid and erythromycin),
as well as Pseudomonas aeruginosa. She was
treated with intravenous vancomycin,
ceftazidime and tobramycin. As the MRSA
persisted, vancomycin was replaced with
intravenous linezolid, followed by a course
of oral linezolid and trimethoprim–sulfa-
methoxazole. More than a year after her
original illness, she continues to have a
productive cough and requires nebulised
tobramycin to prevent exacerbations.
The patient’s only risk factor was contact
with her mother, who had an MRSA buttock
abscess incised several months earlier. Phage
typing and pulsed-field gel electrophoresis
revealed that the mother’s and daughter’s
isolates were identical (Box). They were
found to belong to the Queensland strain of
community-acquired MRSA (CA-MRSA)
and to possess Panton–Valentine leukocidin,
a virulence factor which is highly associated
with necrotising pneumonitis and invasive
primary skin infection.1
CA-MRSA is a growing problem in Aus-
tralia, and severe pneumonia due to this
organism has recently been reported in
adults.2,3 The isolation of CA-MRSA before
prolonged courses of antibiotics, its charac-
terisation as a virulent strain, the response to
appropriate treatment and the recrudes-
cence of symptoms on cessation of therapy
demonstrate that it was the causative organ-
ism in this case. The case is also noteworthy
for the documented intrafamilial spread and
the fact that the patient did not belong to the
Pacific Islander community, in which CA-
MRSA infections in south-western Sydney
most commonly occur.4
Most S. aureus strains in the community
are sensitive to flucloxacillin and dicloxacil-
lin, so these remain the empirical treatments
of choice, unless CA-MRSA is isolated or
strongly suspected. CA-MRSA strains are
non-multiresistant, and oral antibiotic
options include clindamycin, trimethoprim–
sulfamethoxazole or rifampicin and fusidic
acid.5 Intravenous vancomycin is commonly
used in severe infections, but recent evi-
dence suggests that linezolid, an oxazoli-
dinone antibiotic with efficacy against
multiply resistant bacteria, including MRSA,
penicillin-resistant Streptococcus pneumoniae
and vancomycin-resistant enterococci, may
be more effective.6 Issues of cost, toxicity,
local availability, potential development of
resistance and sensitivity of isolates in vitro
need to be considered before determining
appropriate treatment.
In conclusion, clinicians should be aware
of the growing problem of CA-MRSA and
the potentially devastating consequences of
infection with this organism, even in other-
wise healthy children.
Acknowledgements: We thank Dr Michael Free-
lander and Dr Andrew Numa for their assistance in
the management of this case; SEALS Microbiology
for provision of isolates; Alison Vickery and Yvonne
Kwok (SWAPS Staphylococcal Reference Facility)
for performing phage typing and polymerase chain
reaction for Panton–Valentine leukocidin. Dr Brad-
ley Martin and Dr Emma Best are supported by the
Sydney Children’s Hospital Foundation.
1 Gillet Y, Issartel B, Vanhems P, et al. Association
between Staphylococcus aureus strains carrying
gene for Panton-Valentine leukocidin and highly
lethal necrotising pneumonia in young immuno-
competent patients. Lancet 2002; 359: 753-759.
2 Nimmo GR, Playford EG. Community-acquired
MRSA bacteraemia: four additional cases including
one associated with severe pneumonia [letter]. Med
J Aust 2003; 178: 245. 
3 Peleg AY, Munckhof WJ. Fatal necrotising pneumo-
nia due to community-acquired methicillin-resistant
Staphylococcus aureus (MRSA) [letter]. Med J Aust
2004; 181: 228-229. 
4 Gosbell IB, Mercer JL, Neville SA, et al. Non-
multiresistant and multiresistant methicillin-resist-
ant Staphylococcus aureus in community-acquired
infections. Med J Aust 2001; 174: 627-630.
5 Marcinak JF, Frank AL. Treatment of community-
acquired methicillin-resistant Staphylococcus
aureus in children. Curr Opin Infect Dis 2003; 16:
265-269.
6 Wunderink RG, Rello J, Cammarata SK, et al. Line-
zolid vs vancomycin. Analysis of two double-blind
studies of patients with methicillin-resistant Staphy-
lococcus aureus nosocomial pneumonia. Chest
2003; 124: 1789-1797. ❏
Impact of a formal removal 
policy for central venous 
catheters on duration of 
catheterisation
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TO THE EDITOR: Bloodstream infections
are frequent in healthcare settings and cause
significant mortality and morbidity.1,2 Most
of these infections are caused by intravenous
catheters, particularly central venous cathe-
ters (CVCs). Over 250 000 catheter-related
bloodstream infections occur annually in
the United States,1 and over 3000 in Aus-
tralia.2 Many CVCs are retained when no
longer essential. For example, a recent one-
day audit in a US teaching hospital found
that 15% of CVCs (11/74) were “unjusti-
fied”; most of these had been inserted in the
intensive care unit but retained unecessarily
after discharge from the unit.3
The risk of bloodstream infection is much
higher with CVCs than with peripheral
venous catheters (4.0 versus 0.2 per 1000
line-days).2,4 Such simple facts are often
overlooked or inadequately emphasised in
preventive programs, and CVCs may be
retained for convenience.
Pulsed-field gel electrophoresis 
(PFGE) of Staphylococcus aureus 
strains
1. Low-range PFGE marker.
2. Control S. aureus strain (NCTC 8325).
3. S. aureus isolate from patient.
4. S. aureus isolate from mother. 
5. Queensland strain of community-
acquired methicillin-resistant S. aureus 
(CA-MRSA).MJA • Volume 182 Number 5 • 7 March 2005 249
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informal clinical practice of routinely
removing CVCs when patients were dis-
charged from the unit. However, an audit
found that many CVCs were retained, often
inappropriately, thus exposing patients to
needless increased risk.5 A formal interven-
tion policy aimed at improving CVC
removal was implemented. This included a
month of staff education, culminating in
introduction of a formal written policy in
March 2003. CVCs were to be removed
when no longer clinically required or at
discharge from the intensive care unit,
unless the patient met predetermined
retention criteria (ie, administration of
vasoactive or venotoxic drugs [eg,
dopamine or vancomycin] or parenteral
nutrition solutions; poor peripheral venous
access [after two attempts] with ongoing
need for intravenous therapy; or transfer to
another intensive care or coronary care
unit).
We undertook a prospective observa-
tional study of all patients with CVCs in the
intensive care unit of our hospital in the
period March to August 2003. Patients
were grouped according to whether the
CVC was removed per policy before or at
discharge from the intensive care unit;
whether it was retained per policy at dis-
charge from the unit; or whether it was
retained in breach of policy. All patients
were followed up for 7 days after CVC
removal. Those who died within this time
were excluded from the analysis.
We studied a total of 305 CVCs in 272
patients (Box). We observed:
• high compliance with the written policy
(91%),
• significantly lower CVC in-situ times
when policy was followed (5.1 v 8.1 days),
• low CVC reinsertion rates (7%),
• no difference in incidence of blood-
stream infections between the groups.
This study demonstrates that a formal
policy directed at early CVC removal is
effective in lowering CVC in-situ times
without incurring clinical cost to the
patients (eg, excessive CVC reinsertion
rates). Policy breaches were infrequent (8%
of all CVCs), but, when they occurred,
CVC retention appeared unnecessary, and
CVC in-situ times were significantly pro-
longed. The risk of sepsis with CVCs may
be substantially lowered by policy-driven
removal of CVCs, without compromising
patient care.
1 O’Grady NP, Alexander M, Dellinger EP, et al.
Guidelines for the prevention of intravascular
catheter-related infections. Centers for Dis-
ease Control and Prevention. MMWR
Recomm Rep 2002; 51 (RR-10): 1-26.
2 Collignon PJ. Intravascular catheter associ-
ated sepsis: a common problem. The Austral-
ian  S tud y  on In travascu lar  Catheter
Associated Sepsis. Med J Aust 1994; 161: 374-
378.
3 Trick WE, Vernon MO, Welbel SF, et al. Unnec-
essary use of central venous catheters: the
need to look outside the intensive care unit.
Infect Control Hosp Epidemiol 2004; 25: 266-
269.
4 McLaws ML, Taylor PC. The hospital Infection
Standardised Surveillance (HISS) programme:
analysis of a two-year pilot. J Hosp Infect
2003; 53: 259-267.
5 Gowardman JR, Brosnan M, Whiting J, Colli-
gnon P. Central venous catheters: optimal
patient care or convenience? [letter]. Med J
Aust 2004; 180: 595-596. ❏
Inhalation-device 
polypharmacy in asthma
Vanessa M McDonald,* 
Peter G Gibson†
* Clinical Nurse Consultant, † Professor, Department 
of Respiratory and Sleep Medicine, John Hunter 
Hospital, Locked Bag 1, Hunter Region Mail Centre, 
Newcastle, NSW 2310.
Peter.Gibson@hunter.health.nsw.gov.au
TO THE EDITOR: The delivery of asthma
drugs via inhalation offers the best balance
between efficacy and safety. However, poor
inhalation technique limits the efficacy of
this approach. In recent years, there has
been a progressive increase in the types of
inhalation devices used in asthma manage-
ment. We questioned whether this would
lead to “inhaler-device polypharmacy”, a
Comparison of patient characteristics and CVC outcomes when removal policy 




P (policy  





retained* Total CVC retained 
Patient characteristics
Number of patients 176 71 247 25
Age (years) (SD) 60.2 (17.9) 64.9 (15.7) 61.7(17.5) 69.0 (15.3) 0.02
ICU length of stay (days) (SD) 4.7 (8.2) 3.3 (5.2) 4.3 (7.6) 2.1 (2.0) 0.06
APACHE II score (SD) 14.7 (6.9) 14.8 (7.0) 14.6 (17.5) 14.2 (5.1) 0.31
Ventilation time (h) (SD) 51 (89) 46 (123) 51 (103) 31(55) 0.19
CVC outcomes
No. of CVCs (% of all CVCs) 202 (66%) 77 (25%) 279 (91%) 26 (8%) nt
In-situ time 
 Hours (SD) 97 (115) 202 (186) 124 (148) 197 (136) 0.009
 Days 4.0 8.4 5.1 8.1
Tips cultured (% of CVCs) 136 (67%) 51 (66%) 187 (67%) 19 (73%) nt
Tips infected (% of CVCs) 20 (9%) 11 (14%) 31 (11%) 4 (15%) 0.51
Catheter-related bloodstream 
infections
 Total no. 2 (1%) 0 2 (1%) 1 (4%) nt
 Per 1000 CVC days 2.5 0 1.4 6.0 0.33
CVC reinsertions (% of CVCs) 15 (7%) 4 (5%) 19 (7%) 0 0.38
Mean no. of ports idle (per day) na 1.5 na 1.6 nt
Peripheral catheters
 Total no. 260 36 296 50 nt
 Mean no. per patient 1.5 0.5 1.2 0.5 nt
 Mean in-situ time (h) 63 66 64 81 nt
CVC = central venous catheter. nt = not tested. na = not applicable. 
* Reasons for appropriate CVC retention were drug administration (32%), poor peripheral access (34%), 
transfer to another high dependency unit (25%) and total parenteral nutrition (9%).250 MJA • Volume 182 Number 5 • 7 March 2005
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tiple types of inhalation device to deliver
his or her asthma medications. We con-
ducted a novel investigation of this issue in
2004.
We examined the computerised records
of adults with asthma who had been
enrolled in a standardised, evidence-based
asthma management and education
program1 between 2000 and 2004. We
noted the number and type of inhaler
devices used, as well as competence with
each device (a trained asthma educator had
observed and scored inhalation technique).
We defined “inhaler-device polypharmacy”
as the use of two or more different types of
inhalation device. The devices assessed in
the education program included a pressu-
rised metered-dose inhaler (with and with-
out a spacer), turbuhaler, accuhaler,
aeroliser, autohaler, and handihaler. Neb-
uliser use was not included in the evalua-
tion.
We assessed a total of 511 patients:
278 (107 male; mean age, 37 years)
between1 January 2000 and 1 January 2002
(Period 1), and 233 patients (55 male; mean
age, 40 years) between 2 January 2002 and
1 January 2004 (Period 2).
Period 1 patients were distinct from
Period 2 patients in that the latter began
their treatment after the release of combi-
nation asthma therapy in a single inhaler,
when polypharmacy may have been
expected to diminish.
Inhaler-device polypharmacy was
present in 203 (73%; 95% CI, 68%–78%)
patients during Period 1 and 164 (70%;
64%–75%) in Period 2 (P = 0.3) (Box).
In Period 1, inhalation technique was
inadequate with at least one device in 58
(29%) patients using inhaler polypharmacy
and in 19 (25%) using only one device
(Box). In Period 2, inhalation technique
was inadequate with at least one device in
85 (52%) patients using inhaler polyphar-
macy and in 25 (36%) using only one
device. In both Period 1 and Period 2
patients, inadequate inhaler technique with
at least one device increased with the
number of devices used (P values 0.02 and
0.05, respectively) (Box).
We conclude that inhaler-device poly-
pharmacy is a common problem among
adults with asthma. Inadequate inhalation-
device technique is also common, espe-
cially among patients using three or more
delivery devices. Inhaler-device polyphar-
macy could lead to poor asthma control
through inadequate delivery of medication.
Patients with poor asthma control should
be evaluated for their asthma management
skills, including competency in using
inhaler devices. These skills should be
optimised before a new drug and/or device
is added to their treatment regimen. We see
no justification for the use of more than
two inhalation delivery devices in asthma
management.
1 Gibson PG, Wilson AJ. The use of continuous
quality improvement methods to implement prac-
tice guidelines in asthma. J Qual Clin Pract 1996;
16: 87-102. ❏
Smoking and pregnancy
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TO THE EDITOR: Problems with inter-
preting odds ratios reported in meta-analy-
ses of smoking-cessation interventions
have recently been highlighted.1 Ford and
Dobson2 have erred in a different way
when applying the findings of the
Cochrane review on smoking cessation
interventions in pregnancy3 to calculate the
public health benefits of delivering such
interventions to all pregnant women in
Australia.
When all methodologically acceptable
randomised controlled trials were consid-
ered, the Cochrane review did find the
prevalence of smoking at end-of-pregnancy
was 6% lower in intervention than control
groups.3 However, this does not equate to a
6% reduction in the population prevalence
of smoking among pregnant women, as
Ford and Dobson assume. A mean between-
group difference reported in a meta-analysis
is not equivalent to a difference of exactly
the same magnitude in a population preva-
lence of a risk factor unless 100% of the
population exhibit that risk factor. Clearly,
as Ford and Dobson have reported, this is
not the case with smoking in pregnancy,
where they correctly note that about 20% of
pregnant women report current smoking at
their first antenatal visit.2 Therefore, smok-
ing-cessation interventions would not
reduce the prevalence of smoking by 6%
from 20% to 14%. The expected reduction
can be calculated as follows: expected
reduction in prevalence of smoking in preg-
nant women = current smoking prevalence
in pregnant women (20%)  between-group
difference in smoking prevalence (0.06) =
1.2%.
This calculation rests on two assumptions:
namely, that all pregnant women in Australia
currently receive usual smoking-cessation
care equivalent to that of control group
conditions in the Cochrane review3 and that,
in the short term, antenatal care can be
transformed to the point where all future
pregnant women receive smoking-cessation
care equivalent to that received by those in
intervention groups in the Cochrane review.
Therefore, it is obvious that the expected
smoking prevalence of 18.8% (20% minus
1.2%) is considerably higher than the 14%
calculated by Ford and Dobson.2 Unfortu-
nately, this means the rates of reduced infant
deaths, hospital separations and costs to the
healthcare system estimated by Ford and
Dobson have also been overstated.
In summary, the gains to be expected by
clinical interventions with pregnant smokers
are modest. Furthermore, past evaluations of
media campaigns directed specifically at
pregnant women have not shown significant
positive effects.4 This reinforces the impor-
tance of tobacco-control strategies which tar-
get the whole population in addition to those
which target pregnant women.5
1 Walsh RA. Interpreting odds ratios: examples from
smoking cessation research. Aust N Z J Public
Health 2004; 28: 389.
2 Ford JH, Dobson AJ. Smoking and pregnancy [let-
ter]. Med J Aust 2004; 181: 285-286.
3 Lumley J, Oliver SS, Chamberlain C, Oakley L.
Interventions for promoting smoking cessation dur-
Number of asthma patients using single or multiple inhalation devices and 
proportion of those patients with inadequate technique, over two time periods
One device Two devices Three or more devices
Period 1* (n = 278) 75 (27%) 150 (54%) 53 (19%)
Period 2† (n = 233) 69 (30%) 129 (55%) 35 (15%)
Patients with inadequate inhalation-device technique
Period 1* 19/75 (25%) 35/150 (23%) 23/53 (43%)
Period 2† 25/69 (36%) 64/129 (50%) 21/35 (60%)
* 1 Jan 2000–1 Jan 2002. † 2 Jan 2002–1 Jan 2004.MJA • Volume 182 Number 5 • 7 March 2005 251
LETTERSing pregnancy. The Cochrane Database of System-
atic Reviews 2004, Issue 3. Art. No: CD001055. pub
2. DOI: 10.1002/14651858.
4 Walsh R, Redman S. Smoking cessation in preg-
nancy: do effective programmes exist? Health Pro-
mot Int 1993; 8: 111-127.
5 Lowe JB, Wakefield M. Smoking and pregnancy:
time to implement evidence-based solutions. Aust
N Z J  Public Health 1998; 22: 523. ❏
Jessica H Ford,* Annette J Dobson†
* Research Assistant, † Professor of Biostatistics, 
School of Population Health, University of Queens-
land, Herston Road, Herston, Brisbane, QLD 4006.
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IN REPLY: We thank Walsh and Lumley for
correcting the error in our letter. The 6%
reduction in smoking during pregnancy
referred to an absolute difference in preva-
lence of continued smoking in late preg-
nancy among women who smoked early in
pregnancy, from 91% in the control groups
to 85% in the treatment groups.1 We incor-
rectly hypothesised a reduction from 20% to
14% in prevalence of any smoking during
pregnancy.
In fact, there was a decline in smoking
during pregnancy, from 22% in 1994 to
17% in 2001 in New South Wales.2 These
figures illustrate well the final point that
Walsh and Lumley make: whole-of-popula-
tion approaches to smoking reduction can
yield much greater benefits (a 5% reduction
in 7 years in NSW) than high-risk
approaches (from our data, the 1.2% calcu-
lated by Walsh and Lumley).
Our estimates of the adverse effects of
smoking in pregnancy are, at present, cor-
rect. Although we unfortunately overstated
the possible reductions resulting from inter-
ventions targeted only at pregnant women,
such reductions are plausible for whole-of-
population approaches.3
1 Lumley J, Oliver SS, Chamberlain C, Oakley L.
Interventions for promoting smoking cessation dur-
ing pregnancy. The Cochrane Database of System-
atic Reviews 2004, Issue 3. Art. No: CD001055. pub
2. DOI: 10.1002/14651858.
2 Centre for Epidemiology and Research, NSW
Department of Health. New South Wales Mothers
and Babies 2001, NSW Public Health Bull 2002;
13(S-4).
3 Rose G. The strategy of preventive medicine.
Oxford: Oxford University Press, 1992. ❏
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TO THE EDITOR: Gray, Yeo and Duckett
used the wrong basis of measure for their
analysis of bed trends.1 Bed use per thou-
sand of the population masks the trends in
total bed-days or separations and does not
address the issue of supply. These issues
have important ramifications for policy
decision-making.
Using the same sources of data,2,3 we
compared bed-related statistics and popu-
lation changes for the periods 1993–94
and 2001–02. What should be of most
interest to planners is that the number of
multi-day bed-days only declined margin-
ally (from 14 434 to 14 231; −1.4%),
despite the significant increase (from 1698
to 3343; + 96.8%) in same-day activity.
Although multi-day separations and
bed-days did decline (separations, −4.2%;
bed-days, −14.9%) for those aged 65–74
years, for those aged 75 years or over bed-
days and separations increased signifi-
cantly (separations, + 41.6%; bed-days,
+27.7%). Furthermore, same-day activity
increased significantly for those aged 65
or more years.
Furthermore, the authors failed to high-
light the implications of changes in the
relative age mix of activity. For those aged
75 years or more, the increase in propor-
tion of separations (+ 5.8 percentage
points) and bed-days (+ 1.8 percentage
points) was greater than the increase in
this proportion of the population (+ 1.1
percentage points). For the 65–74-years
age group, the proportion of same-day
hospital activity increased (+ 1.3 percent-
age points), unlike the reduction in that
proportion of the population (−0.2 per-
centage points).
Moreover, the question of whether an
ageing population has resulted in the need
for more beds can not be answered with-
out considering the supply of beds. From
our experience, the growth in same-day
activity has been achieved, at least in part,
by substituting same-day beds for inpa-
tient beds. The need for increased same-
day beds has been considerable. Statistics
relating to same-day beds do not appear to
be reported for Australia as a whole.
However, the increasing implied bed
occupancy (including same-day) shown in
the Box supports this conclusion.
We surmise that the reduction in supply
of multi-day beds combined with a mar-
ginally altered demand for multi-day beds
has led to increasing numbers of bed
crises. Given that relative growth in same-
day activity can be attributed to people
aged 65 years or over, and that the
number of multi-day bed-days for those
aged 75 years or more has increased, it
appears that the ageing of the population,
combined with the manner in which the
substitution of beds has occurred, has
contributed to increasing bed crises.
Competing interests. None identified. The views
of Mark Mackay are personal and in no way
represent those of his employer.
1 Gray LC, Yeo MA, Duckett SJ. Trends in the use of
hospital beds by older people in Australia: 1993–
2002. Med J Aust 2004; 181: 478-481. 
2 Australian Bureau of Statistics. Australian histori-
cal population statistics. 3. Population age–sex
structure. Canberra: ABS, 2002. (ABS Catalogue
No. 3105.0.65.001.)
3 Australian Institute of Health and Welfare. Austral-
ian hospital statistics 2002–03. Health Services
Series No. 22. Canberra: AIHW, 2004. (AIHW Cata-
logue No. HSE 32.) ❏
Changes in implied bed occupancy
Financial year
Change from 1998–99 
to 2001–021998–99 1999–00 2000–01 2001–02
Total bed-day 
utilisation (000s)
22 323 22 597 22 467 23 218 + 4.0%
Total available bed-
days (000s)
28 868 28 540 28 675 28 787 −0.3%
Implied occupancy 77% 79% 78% 81% + 4.3%252 MJA • Volume 182 Number 5 • 7 March 2005
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IN REPLY: Mackay and Millard have raised
some important issues in relation to our
analysis. Our article was developed to
encourage wider reflection and their
response is thus welcomed.
The primary criticism levelled by
Mackay and Millard was that we under-
played the importance of supply of beds in
our interpretation of the trends. We agree
that bed supply is an important driver of
utilisation patterns. We acknowledged
this, in part, in the discussion as a possible
explanation for rising separation and
declining bed-utilisation rates in the older
patient population. We are also sympa-
thetic to the hypothesis that there may be a
process of substitution of same-day separa-
tions for multi-day separations.
However, data relating to bed availabil-
ity are not readily available, and thus could
not be included in our study. Our article
was designed to highlight different trends
between age groups, which have not previ-
ously been reported. Now that these trends
have been identified, further research and
analysis is required to fully explain them,
with a view to supporting an intelligent
strategy to prepare for future population
ageing. ❏
Whistleblowing in the 
Australian public hospital 
system
Paddy A Dewan
Head of Paediatric Surgery, Sunshine Hospital, 
PO Box 152, Parkville, VIC 3052. 
Paddy.dewan@wh.org.au
TO THE EDITOR: Three recent articles in
the MJA about complaints by patients
attending hospital,1 attitudes of hospital staff
t o wa rd  in c i den t  re po r t ing 2  a n d
whistleblowing3 show that complaints are
common, that cultural change is needed to
allow staff to understand that a complaint
from a patient or staff member should be
viewed as an opportunity for change, and
that quality assurance sometimes relies on
whistleblowers but does not always appreci-
ate their efforts.
Faunce and Bolsin report on three
whistleblower incidents,3 but fail to men-
tion one at the Royal Children’s Hospital,
Melbourne, in which I was involved.
Attempts to highlight deficiencies in deliv-
ery of paediatric surgical care and concerns
about the response to adverse events were
managed with threatening tactics (of dis-
missal) by the division of surgery. This was
followed by a hospital board investigation
that, in my opinion, had neither the skill
mix nor the terms of reference to adequately
investigate the quality of care or the bully-
ing. The subsequent investigation by the
Department of Human Services involved
narrowly focused terms of reference and
failed to consider outcomes in some circum-
stances, thereby facilitating the “shooting of
the messenger”.
Current legislation does not effectively
allow for dealing with threatening behaviour
in the workplace, particularly when the
refusal to look at complaints and adverseMJA • Volume 182 Number 5 • 7 March 2005 253
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beyond the confines of the hospital
involved. The Community Advisory Com-
mittee parliamentary enquiry was held in
camera, with evidence being kept from the
public. Worksafe legislation on bullying
does not deal well with the complex situa-
tions that arise in the healthcare industry.4
The Colleges and other professional bod-
ies, such as the AMA and the Medical
Boards, need to take a proactive rather than
a reactive role if further whistleblower inci-
dents are to be avoided.
I concur with the statement of Faunce and
Bolsin that: “Even after substantiation of
their allegations, the whistleblowers . . .
received little respect and support from their
institutions or professions”.3 From personal
experience, I am very aware of the lack of
support that stems from an ethos wary of
public criticism, and the reactive bullying to
which the whistleblower is often subjected.
Until the culture of healthcare focuses on
quality and caring, whistleblower sagas will
continue to occur.
1 Taylor DMcD, Wolfe RS, Cameron PA. Analysis of
complaints lodged by patients attending Victorian
hospitals, 1997–2001. Med J Aust 2004; 181: 31-35.
2 Kingston MJ, Evans SM, Smith BJ, Berry JG. Atti-
tudes of doctors and nurses towards incident
reporting: a qualitative analysis. Med J Aust 2004;
181: 36-39.
3 Faunce TA, Bolsin SNC. Three Australian whistle-
blowing sagas: lessons for internal and external
regulation. Med J Aust 2004; 181: 44-47.
4 Worksafe Victoria. Workplace bullying and occupa-
tional  v iolence. Avai lab le at : www.work-
cover.vic.gov.au/dir090/vwa/home.nsf/pages/b&v_
intro (accessed Jan 2005). ❏
The direct thrombin inhibitor 
melagatran/ximelagatran
Luke R Bereznicki,* Shane L Jackson,† 
Gregory M Peterson‡
* PhD Candidate, † Research Fellow, ‡ Professor of 
Pharmacy, Unit for Medication Outcomes Research 
and Education, University of Tasmania, Private Bag 
26, Hobart, Tasmania 7001. lberezni@utas.edu.au
TO THE EDITOR: If a new drug such as
ximelagatran is to be considered as a
replacement for warfarin in preventing the
thromboembolic complications associated
with atrial fibrillation (AF), drug cost
becomes an important issue. Brighton’s
recent article in the Journal,1 while com-
prehensive, does not discuss the cost-
effectiveness of ximelagatran treatment.
Ximelagatran was approved in several
European countries for the prevention of
venous thromboembolism associated with
orthopaedic surgery. The cost of the drug
for this indication (24 mg given twice
daily) is 4.5 euros (A$7.7) per day.2 This
represents the best available estimate of
the cost of using ximelagatran for AF,
although the dose is higher in AF (36 mg
twice daily), and there are limitations in
applying the drug cost in one country to
another country.
Routine monitoring of the antithrom-
botic effect of ximelagatran (ie, interna-
tional normalised ratio [INR] testing) was
not conducted in clinical trials. While this
is potentially advantageous, frequent test-
ing of alanine aminotransferase (ALT) lev-
els is recommended at baseline and
monthly for the first 6 months of therapy,
every second month for the remainder of
the first year, and every third month there-
after, for safety reasons.3 This is because
some patients taking ximelagatran will
develop elevated ALT levels (about 6.1% of
patients to greater than threefold normal,
and 3.4% to greater than fivefold normal)
when ximelagatran therapy is com-
menced.3
The costs of INR and ALT tests are very
similar (about $25 and $22, respectively).
Estimated costs of treating 1000 patients with atrial fibrillation (AF) with 
ximelagatran or warfarin for the first year of therapy.
Ximelagatran* Warfarin†
Total cost $2 803 821.00 $106 800.00
Cost per patient $2 803.82 $106.80
Monitoring
Test (frequency/year) ALT (10)‡ INR (20)§
Total cost $217 000.00 $507 000.00
Cost per patient $217.00 $507.00
Major bleeding¶
Annual incidence** 1.6% 2.2%
No. of expected events 16 22
Total cost $38 730.00 $53 253.00
Ischaemic stroke††
Annual incidence‡‡ 1.6% 1.6%
No. of expected events 16 16
Total cost $101 936.00 $101 936.00
Overall cost
Total $3 161 487.00 $768 989.00
Per patient $3 161.49 $768.99
Cost difference compared with warfarin
Total $2 392 498.00 —
Per patient $2 392.50 —
ALT =Alanine aminotransferase. INR = International normalised ratio.
* Cost of giving ximelagatran (24 mg twice-daily) to prevent venous thromboembolism post-surgery (German 
data; the dose for prevention of thromboembolism in AF is 36 mg twice-daily).3
† Cost of warfarin taken from the Australian Pharmaceutical Benefits Scheme, December 2004.
‡ Monitoring cost derived from the cost of conducting ALT testing (Medicare Benefits Schedule, December 
2004) according to the manufacturer’s directions (tests at baseline, monthly for the first 6 months, 2-monthly for 
remainder of the first year).
§ Cost derived from Medicare Benefits Schedule (December 2004) based on a frequency of 20 tests per annum.
¶ The cost of a hospital admission caused by a major bleed was $2420.60 in Australia for the years 2002–2003 
(estimate based on 2002–2003 public hospital data).4 Intracranial haemorrhage may be associated with 
significant ongoing costs, but a smaller proportion of major bleeding incidents.
** No significant difference between warfarin and ximelagatran in either SPORTIF III5 or V;6 statistically 
significant when data from both trials were combined at P <0.05.
†† Cost ($6371) taken from the NEMESIS study7 and covers acute admission to an Australian hospital with 
ischaemic stroke only; this is an underestimate of the ongoing costs associated with ischaemic stroke. 
‡‡ No significant difference between warfarin and ximelagatran in SPORTIF III5 and V;6 no significant difference 
when data from both trials were combined at P < 0.05.254 MJA • Volume 182 Number 5 • 7 March 2005
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frequent with warfarin than ALT testing
with ximelagatran, the cost difference
associated with therapeutic monitoring
would remain far less than the likely cost
of ximelagatran. We estimate the cost asso-
ciated with treating 1000 patients with AF
with ximelagatran instead of warfarin for 1
year, taking into account drug costs, mon-
itoring costs and the slight difference in
major bleeding rates, to be about $2.4
million (Box).
A United States Food and Drug Admin-
istration advisory committee has recently
raised concerns about the safety of ximela-
gatran (after episodes of severe liver dam-
age), and has recommended that it not be
granted any indication for use without
further safety data. In particular, ALT mon-
itoring did not prevent 3 deaths attri-
butable to x imelagat ran-associa ted
hepatocellular necrosis.3 In light of the
recent withdrawal of rofecoxib (Vioxx;
Merck Sharp & Dohme), warfarin carries
the intangible benefits of a long and
proven track record. It certainly requires
careful management and ongoing monitor-
ing, but healthcare resources might be
better spent on improving the use of war-
farin rather than paying substantially
increased costs for a drug with similar
efficacy and an uncertain safety profile.
1 Brighton TA. The direct thrombin inhibitor melagat-
ran/ximelagatran. Med J Aust 2004; 181: 432-437. 
2 Controversial: oral thrombin inhibitor ximelagat-
ran (exanta). Available at: www.arznei-tele-
gramm.de/journal/j_0407_a.html (accessed Dec
2004).
3 US Food and Drug Administration: Statistical
review and evaluation-clinical studies (Exanta 36
mg bid oral  formulat ion) .  Avai lab le at :
www.fda.gov/ohrms/dockets/ac/04/briefing/
2004-4069b1.htm (accessed Dec 2004).
4 Australian Institute of Health and Welfare. Aus-
tralian hospital statistics 2002–03. Available at:
www.aihw.gov.au/publications/index.cfm/title/
10015 (accessed Dec 2004).
5 SPORTIF III Investigators. Stroke prevention with
the oral direct thrombin inhibitor Ximelagatran
compared with warfarin in patients with non-
valvular atrial fibrillation (SPORTIF III): ran-
domised controlled trial. Lancet 2003; 362: 1691-
1698.
6 Stroke prevention using the oral direct thrombin
inhibitor Ximelagatran in patients with nonvalvu-
lar atrial fibrillation (SPORTIF V). Late-breaking
clinical trial abstracts [abstract]. Circulation 2003;
108: 2723. Available at: http://circ.ahajour-
nals.org/cgi/content/full/108/21/2723 (accessed
Feb 2005)
7 Dewey HM, Thrift AG, Mihalopoulos C, et al.
Lifetime cost of stroke subtypes in Australia:
findings from the North East Melbourne Stroke
Incidence Study (NEMESIS). Stroke 2003; 34:
2502-2507. ❏
Australasian Association of 
Doctors’ Health Advisory 
Services
Donald B Reid
Co-convenor, Colleague of First Contact
PO Box 896, Bridgetown, WA 6255
dbreid@hotlinks.net.au
TO THE EDITOR: Thank you for your in-
depth look at some of the concerns in
doctors’ health in the October 2004 issue of
the MJA.1
I believe it would have been useful to
include in the issue some practical informa-
tion for doctors wanting to seek help, either
for themselves or for a colleague.
The attached table of contact phone num-
bers does not cover every state and territory,
but it is a starting point. The services offered
are confidential, and can be anonymous if
desired. In Western Australia, the contact
can include access to a list of doctors willing
and able to be GPs for their colleagues.
Further information is available on the Doc-
tors’ Health Advisory Service website
<www.doctorshealth.org.au>.
Editor’s note: The AMA website also has a
very useful “Doctors’ Health Database” at
<www.ama.com.au/web.nsf/tag/doctors-
health-database>.
1 Doctors’ health. Med J Aust 2004; 181 (7). ❏
Prescription shoppers line
Max Kamien
Emeritus Professor, Senior Research Fellow
Discipline of General Practice
University of Western Australia, Perth, WA
mkamien@cyllene.uwa.edu.au
TO THE EDITOR: Over the past two
years, the Journal has pointed out the
health hazards and the lack of logic in the
Health Insurance Commission’s closure of
its previously cost-effective and successful
“Doctor Shopping Hotline”.1-4 But it has
taken the death of a 25-year-old “prescrip-
tion shopper” in Cairns, his crusading
mother, a scathing report by the Queens-
land Coroner5 and public exposure of
these problems by Mark Bannerman on
ABC TV (The 7.30 Report, 22 Dec 2004) for
discernible action to occur.
On that program, the Federal Minister of
Health and Ageing promised that a “Pre-
scription Shopper Line” would be up and
running by the end of January 2005, and
indeed it was activated on 31 January.
This leaves two outstanding issues. The
first is for the Health Insurance Commis-
sion to engage in an open exercise of
mutual education by clearly reviewing its
process of thinking in closing the previ-
ously successful Doctor Shopping Hotline
and its lack of urgency in reinstituting its
proposed better and broader successor.6
The second, and more important, issue
is in understanding the underlying factors
and thought processes of those doctors
whom prescription shoppers describe as
an “easy touch”.7,8
1 Kamien M. Doctor shoppers’ rights: privacy or
lunacy? [letter]. Med J Aust 2003; 178: 248. 
2 Kamien M. “Doctor shoppers”: at risk by any
other name [editorial]. Med J Aust 2004; 180: 204-
205. 
3 Martyres RF, Clode D, Burns JM. Seeking drugs or
seeking help? Escalating “doctor shopping” by
young heroin users before fatal overdose. Med J
Aust 2004; 180: 211-214. 
4 Hart JM. “Doctor shoppers”: at risk by any other
name [letter]. Med J Aust 2004; 181: 342-343. 
5 Inquest into the cause and circumstances sur-
rounding the death of George Shoobridge.
28102004 D9 T4/GRB m/T CAIR03/298 (Previtera,
Coroner).
6 Whalan I. “Doctor shoppers”: at risk by any other
name [letter]. Med J Aust 2004; 181: 343. 
7 MacQueen AR. “Doctor shoppers”: at risk by any
other name [letter]. Med J Aust 2004; 181: 342. 
8 Breen CL, Degenhardt LJ, Bruno RB, et al. The
effects of  restricting public ly subsid ized
temazepam capsules on benzodiazepine use
among injecting drug users in Australia. Med J
Aust 2004; 181: 300-304. ❏
Australasian Association of Doctors’ 
Health Advisory Services (DHASs): 
helplines for doctors
Victorian Doctors’ Health 
Programme (VIC)
(03) 9495 6011
DHAS (SA) (08) 8273 4111
Colleague of First 
Contact (WA)
(08) 9321 3098
DHAS (NSW) (02) 9437 6552
DHAS (New Zealand) (04) 471 2654
DHAS (QLD) (07) 3833 4352
DHAS (TAS) (03) 6223 2047 
(in hours) 
(03) 6235 4165 
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31 January, 2005, saw the commencement of a new initiative through the
Commonwealth Department of Family and Community Services. The new service
— the National Auslan Interpreter Booking and Payment Service (NABS;
<www.nabs.org.au>) — is available to private medical and healthcare practitioners
and Auslan users free of charge.
Until now the cost of having an Auslan (Australian Sign Language) interpreter at
private medical or healthcare appointments has been borne by either the patient,
or by state deaf societies. This has been recognised as an access and equity issue
for the Australian deaf community and other users of Auslan. As a result, the
Australian Government has allocated $18.4 million over the next 3.5 years to
provide this essential service.
Wesley Mission Brisbane has been selected as the organisation to establish and
operate the service, which operates from a national call centre located at the
corporate office of Wesley Mission on the north side of Brisbane.
The national call centre will operate between 8 am and 8 pm local time in all Australian
states and territories. 
An interpreter to attend appointments with users of Auslan can be booked by:
• Phone (voice):1800 24 69 45 
• Phone (telephone typewriter [TTY]): 1800 24 69 48 
• Fax: 1800 24 69 14 
• Email: bookings@nabs.org.au
• SMS: 0427 671 261
• Post: National Auslan Interpreter Booking and Payment Service, 
930 Gympie Road, Chermside, QLD 4032
NABS provides free interpreting services for private medical appointments with:
• general practitioners and specialists • podiatrists and chiropodists
• Aboriginal health workers • chiropractors
• audiologists • osteopaths
• dietitians • psychologists
• mental health workers • speech pathologists
• occupational therapists • dentists
• physiotherapists • optometrists 256 MJA • Volume 182 Number 5 • 7 March 2005
